TITLE

An early invasive strategy was not better than a selectively invasive strategy for acute coronary syndromes

PUB. DATE
March 2006
SOURCE
ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p30
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on a study which revealed that an early invasive strategy was not better than a selectively invasive strategy for acute coronary syndromes. Nearly 1200 patients who had symptoms of ischemia were observed, that were increasing or occurred at rest in the previous 24 hours. All patients received aspirin, enoxaparin and abciximab during percutaneous coronary intervention. Patients in the early invasive strategy group had higher rates of myocardial infarction and lower rates of rehospitalization.
ACCESSION #
20297580

 

Related Articles

  • Stopping aspirin raises CVD mortality risk.  // Pulse;8/10/2011, Vol. 71 Issue 26, p8 

    The article reports that Spanish researchers have found that cessation of aspirin use as secondary prevention for cardiovascular disease can increase the risk of heart attack or coronary heart disease by 50%.

  • Results from CURRENT-OASIS 7.  // MD Conference Express;Nov2009, p15 

    The article highlights findings of the Clopidogrel optimal loading dose Usage to Reduce Recurrent EveNTs-Organization to Assess Strategies in Ischemic Syndromes (CURRENT-OASIS 7) trial, presented by Professor Shamir Mehta of McMaster Clinic in Hamilton, Ontario, Canada. It is stressed that the...

  • The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Bramlage, P.; Messer, C.; Bitterlich, N.; Pohlmann, C.; Cuneo, A.; Stammwitz, E.; Tebbenjohanns, J.; Gohlke, H.; Senges, J.; Tebbe, U. // Heart;Apr2010, Vol. 96 Issue 8, p604 

    Objectives Five drug classes have been shown to improve the prognosis of acute myocardial infarction in clinical trials: aspirin, b-blockers, statins, renin angiotensin system (RAS) blockers and thienopyridines. We aimed to assess whether the benefits of combining these drugs (termed optimal...

  • Recent Developments in Early Antithrombotic Therapy for Acute Myocardial Infarction. Keating, Friederike K.; Dauerman, Harold L.; Schneider, David J. // Current Medical Literature: Cardiology;2007, Vol. 26 Issue 3, p61 

    The article discusses developments in the treatment of ST-elevation myocardial infarction (STEMI) or non-STEMI. Acute therapy of STEMI is directed towards early vessel patency and the prevention of reinfarction and aspirin is recommended in the initial treatment of acute myocardial infarction...

  • Optimal oral antiplatelet therapy for vascular disease. Tran, H.; Anand, S.S. // BMJ: British Medical Journal (International Edition);1/8/2005, Vol. 330 Issue 7482, p52 

    Poses the question of which antiplatelet agents, used alone or in combination, are effective in preventing recurrent vascular events. Research of multiple databases for trials comparing an antiplatelet regimen to either placebo or a difference regimen; Limitations of the findings which suggest...

  • Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: Perspectives on Combination Therapy. Villareal, Rollo P.; Ferguson, James J.; Wilson, James M.; Kim, Paul // Texas Heart Institute Journal;2001, Vol. 28 Issue 4, p276 

    Examines clinical data on the combination therapies for unstable angina and non-ST-segment elevation, myocardial infarction. Use of aspirin as part of routine therapy for angina; Information on unfractioned heparin; Benefits of using the combination of aspirin and heparin.

  • Myocardial infarction with angiographically normal coronary arteries. Chandrasekaran, B.; Kurbaan, A. S. // Journal of the Royal Society of Medicine;Aug2002, Vol. 95 Issue 8, p398 

    The article focuses on the myocardial infarction with normal coronary arteries (MINCA). MINCA symptoms and electrocardiographic (ECG) findings were similar to myocardial infarction (MI) with angiographic colonary disease except in its infarct size that tend to be smaller. Information related to...

  • Clopidogrel + aspirin therapy worth it in acute coronary syndromes.  // PharmacoEconomics & Outcomes News;3/12/2005, Issue 473, p3 

    Focuses on the impact of the addition of clopidogrel to aspirin therapy on the quality-adjusted life expectancy of patients with high-risk coronary syndromes. Cost effectiveness of antiplatelet therapies to prevent the composite outcome of myocardial infarction, stroke or cardiovascular death...

  • Untitled.  // PharmacoEconomics & Outcomes News;6/17/2006, Issue 505, p1 

    The article discusses research being done on the cost effectiveness of adding clopidogrel to aspirin in treating in-patients with ST-segment elevation myocardial infarction (STEMI). It references a study by Z. Zhang and colleagues in the May 30, 2006 online issue of the "Journal of the American...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics